arrow
C

Christelle Jouannaud

institut godinot
H指数:26
被引数:3,280

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer

早期乳腺癌患者中芳香化酶抑制剂诱导的关节痛预测模型的开发与验证

2026-08-180
PRE
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women

老年转移性三阴性乳腺癌患者的特征、治疗及生存情况:基于ESME mBC真实世界全国队列研究,并与年轻女性进行比较

2026-05-220
OAAI
Return to work among self-employed breast cancer survivors from the CANTO cohort

自雇乳腺癌幸存者重返工作情况:基于CANTO队列的研究

2026-03-120
OAAI
ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors

态度 - 重点关注纵向癌症队列中的失访问题:对乳腺癌幸存者在纵向研究中参与经历和观点的深入定性分析

2026-02-110
OAAI
The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort study
2026-01-150
PRE
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

纳武利尤单抗联合伊匹木单抗与卡培他滨作为新辅助化疗后仍有残留病灶的三阴性乳腺癌患者的术后治疗:一项多中心、随机、开放标签的II期试验——BREASTIMMUNE-03

2025-11-210
OAAI
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study

与乳腺癌2年后重返工作相关的职业条件:队列研究的见解

2025-10-210
PRE
Risk models of cancer-related cognitive complaints among early breast cancer survivors in the CANTO cohort

早期乳腺癌幸存者认知相关投诉的风险模型:CANTO队列研究

2025-10-010
PRE
Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC)

早期乳腺癌(EBC)患者中芳香化酶抑制剂肌肉骨骼毒性(AIMT)预测模型的开发与验证

2024-09-010
PRE
Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy

早期乳腺癌接受新辅助化疗后,初始肿瘤负荷与病理完全缓解概率在分子亚型中的关系

2024-09-010
PRE
Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
2024-05-020
PRE
The magnitude and temporal variations of socioeconomic inequalities in quality of life after early breast cancer: results from the multicentric French CANTO cohort
2024-05-020
PRE
Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC)
2024-05-020
PRE
Association of clonal hematopoiesis (CH) with clinical outcomes among survivors of breast cancer (BC)
2024-05-020
PRE
Prognostic stratification ability of the CPS plus EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
2024-05-012
OA
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort
2023-08-018
PRE